Are blockers of gp120/CD4 interaction effective inhibitors of HIV-1 immunopathogenesis?

AIDS Reviews

Volumn 8, Issue 1, 2006, Pages 3-8

  Herbeuval, Jean Philippe ^a   Shearer, Gene M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

CD4+ T cell apoptosis; HIV 1 immunopathogenesis; Interferon ; Plasmacytoid dendritic cells; sCD4 IgG therapy; TRAIL DR5

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); ALPHA INTERFERON; AMINO ACID DERIVATIVE; ANTIBODY; ANTIRETROVIRUS AGENT; CD 4M33; CD4 ANTIGEN; CD4 IMMUNOGLOBULIN G2; CYTOKINE ANTIBODY; DEATH RECEPTOR 5; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN G; PROTEIN ANTIBODY; SOLUBLE CD4 ANTIGEN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; APOPTOSIS; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE COURSE; EX VIVO STUDY; GENE EXPRESSION; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOGENESIS; LEUKOCYTE; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MONOCYTE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BINDING; PROTEIN SYNTHESIS; REVIEW; VIRUS CELL INTERACTION; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON TYPE I; MEMBRANE GLYCOPROTEINS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; VIRAL ENVELOPE PROTEINS; VIRAL LOAD;

EID: 33646768572     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Levy J. Pathogenesis of HIV infection. Microbiol Rev 1993;57:183-289.
2. Pantaleo G, De Maria A, Koenig S, et al. CD8+ T lymphocytes of patients with AIDS maintain normal broad cytolytic function despite the loss of HIV-specific cytotoxicity. Proc Natl Acad Sci USA 1990; 87:4818-22.
3. Murray M. Tryptophan depletion and HIV infection: a metabolic link to pathogenesis. Lancet Infect Dis 2003;3:644-52.
4. Schnittman S, Greenhouse J, Psallidopoulos M, et al. Increasing viral burden in CD4+ T-cells from patients with HIV infection reflects rapidly progressive immunosuppression and clinical disease. Ann Intern Med 1990;113:438-43.
5. Finkel T, Tudor-Williams G, Banda N, et al. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat Med 1995;1:129-34.
6. Groux H, Torpier G, Monte D, Mouton Y, Capron A, Ameisen J. Activation-induced death by apoptosis in CD4+ T-cells from HIV-infected asymptomatic individuals. J Exp Med 1992;175:331-40.
7. Dianzani U, Bensi T, Savarino A, et al. Role of FAS in HIV infection. Curr HIV Res 2003;1:405-17.
8. Dockrell D. The multiple roles of Fas ligand in the pathogenesis of infectious diseases. Clin Microbiol Infect 2003;9:766-79.
9. Estaquier J, Tanaka M, Suda T, Nagata S, Golstein P, Ameisen J. Fas-mediated apoptosis of CD4+ and CDB+ T-cells from HIV-infected persons: differential in vitro preventive effect of cytokines and protease antagonists. Blood 1996;87:4959-66.
10. Katsikis P, Wunderlich E, Smith C, Herzenberg L. Fas antigen stimulation induces marked apoptosis of T lymphocytes in HIV-infected individuals. J Exp Med 1995;181:2029-36.
11. Westendorp M, Frank R, Ochsenbauer C, et al. Sensitization of T-cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 1995;375:497-500.
12. Vasilescu A, Heath S, Diop G, et al. Genomic analysis of Fas and FasL genes and absence of correlation with disease progression in AIDS. Immunogenetics 2004;56:56-60.
13. + T-cells by a Fas-independent mechanism. J Exp Med 1998;187:1113-22.
14. Badley A, Pilon A, Landay A, Lynch DH. Mechanisms of HIV-associated lymphocyte apoptosis. Blood 2000;96:2951-64.
15. Servet C, Zitvogel L, Hosmalin A. Dendritic cells in innate immune responses against HIV. Curr Mol Med 2002;2:739-56.
16. Marsters S, Sheridan J, Pitti R, et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 1997;7:1003-6.
17. Pan G, Ni J, Wei Y-F, Yu G-I, Gentz R, Dixit V. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997;277:815-8.
18. Sheridan J, Marsters S, Pitti R, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997;277:818-21.
19. Sato K, Hida S, Takayanagi H, et al. Antiviral response by natural killer cells through TRAIL gene induction by IFNα/β. Eur J Immunol 2001;31:3138-46.
20. Tecchio C, Huber V, Scapini P, et al. IFNα-stimulated neutrophils and monocytes release a soluble form of TRAIL (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. Blood 2004; 103:3837-44
21. Ehrlich S, Infante-Duarte C, Seeger B, Zipp F. Regulation of soluble and surface-bound TRAIL in human T-cells, B-cells, and monocytes. Cytokine 2003;24:244-53.
22. Kayagaki N, Yamaguchi N, Nakayama M, et al. Involvement of TRAIL in human CD4+ T-cell-mediated cytotoxicity. J Immunol 1999; 162:2639-47.
23. Smyth M, Cretney E, Takeda K, et al. TRAIL contributes to IFN gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 2001;193:661-70.
24. Vidalain P, Azocar O, Lamouille B, Astier A, Rabourdin-Combe C, Servet-Delprat C. Measles virus induces functional TRAIL production by human dendritic cells. J Virol 2000;74:556-9.
25. Vidalain P, Azocar O, Rabourdin-Combe C, Servet-Delprat C. Measles virus-infected dendritic cells develop immunosuppressive and cytotoxic activities. Immunobiology 2001;204:629-38.
26. Herbeuval J, Lambert C, Sabido O, et al. Macrophages from cancer patients: analysis of TRAIL, TRAIL receptors, and colon tumor cell apoptosis. J Natl Cancer Inst 2003;95:611-21.
27. Griffith T, Chin W, Jackson G, Lynch D, Kubin M. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998;161:2833-40.
28. Gura T. How TRAIL kills cancer cells, but not normal cells. Science 1997;277:768.
29. Liabakk N, Sundan A, Torp S, Aukrust P, Froland S, Espovik T. Development, characterization and use of monoclonal antibodies against sTRAIL: measurement of sTRAIL by ELISA. J Immunol Methods 2002;259:119-28.
30. Stylianou E, Bjerkeli V, Yndestad A, et al. Raised serum levels of interleukin-18 is associated with disease progression and may contribute to virologic treatment failure in HIV-1-infected patients. Clin Exp Immunol 2003;132:462-6.
31. Katsikis P, Garcia-Ojeda M, Torres-Roca J, Tijoe I, Smith C, Herzenberg L. Interleukin-1 β converting enzyme-like protease involvement in Fas-induced and activation-induced peripheral blood T-cell apoptosis in HIV infection. TRAIL can mediate activation-induced T-cell death in HIV infection. J Exp Med 1997;186:1365-72.
32. Lum J, Pilon A, Sanchez-Dardon J, et al. Induction of cell death in HIV-infected macrophages and resting memory CD4 T-cells by TRAIL/Apo21. J Virol 2001;75:11128-36.
33. Jeremias I, Herr I, Boehler T, Debatin K. TRAIL/Apo-2-ligand-induced apoptosis in human T-cells. Eur J Immunol 1998;28:143-52.
34. Miura Y, Misawa N, Maeda N, et al. Critical contribution of TRAIL to apoptosis of human CD4+ T-cells in HIV-1-infected hu-PBL-NOD-SCID Mice. J Exp Med 2001;193:651-60.
35. Lichtner M, Maranon C, Vidalain P, et al. HIV-1-infected dendritic cells induce apoptotic death in infected and uninfected primary CD4 T lymphocytes. AIDS Res Hum Retroviruses 2004;20:175-82.
36. Badley A, Dockrell D, Simpson M, et al. Macrophage-dependent apoptosis of CD4+ T lymphocytes from HIV-infected individuals is mediated by FasL and TNF. J Exp Med 1997;185:55-64.
37. Huang Y, Erdmann N, Peng H, Zhao Y, Zheng J. The role of TRAIL in neurodegenerative diseases. Cell Mol Immunol 2005;2:113-22.
38. Huang Y, Erdmann N, Zhao J, Zheng J. The signaling and apoptotic effects of TRAIL in HIV-1 associated dementia. Neurotox Res 2005;8:135-48.
39. Miura Y, Koyanagi Y, Mizusawa H. TRAIL induces neuronal apoptosis in HIV-encephalopathy. J Med Dent Sci 2003;50:17-25.
40. Herbeuval J, Boasso A, Grivel J, et al. TRAIL in HIV-1-infected patients and its in vitro production by antigen-presenting cells. Blood 2005;105:2458-64.
41. Herbeuval J, Hardy A, Boasso A, et al. Regulation of TRAIL on primary CD4+ T-cells by HIV-1: role of type I IFN-producing plasmacytoid dendritic cells. Proc Natl Acad Sci USA 2005;102:13974-9.
42. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centers. Federation National des Centres de Lutte contre le SIDA. Aids 1997;11:F101-5.
43. Palella F Jr., Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced HIV infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
44. Gulick R, Mellors J, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with HIV infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
45. Dyrhol-Riise A, Voltersvik P, Olofsson J, Asjo B. Activation of CDB T-cells normalizes and correlates with the level of infectious provirus in tonsils during HAART in early HIV-1 infection. Aids 1999;13:2365-76.
46. Badley A, Dockrell D, Algeciras A, et al. In vivo analysis of Fas/FasL interactions in HIV-infected patients. J Clin Invest 1998;102:79-87.
47. Dyrhol-Riise A, Ohlsson M, Skarstein K, et al. T-cell proliferation and apoptosis in HIV-1-infected lymphoid tissue: impact of HAART. Clin Immunol 2001;101:180-91.
48. Gougeon M, Montagnier L. Programmed cell death as a mechanism of CD4 and CD8 T-cell deletion in AIDS. Molecular control and effect of HAART. Ann N Y Acad Sci 1999;887:199-212.
49. Locatelli G, Cancio R, Spadari S, Maga G. HIV-1 reverse transcriptase inhibitors: current issues and future perspectives. Curr Drug Metab 2004;5:283-90.
50. Tozser J. HIV inhibitors: problems and reality. Ann N Y Acad Sci 2001,946:145-59.
51. Herbeuval J, Grivel J, Boasso A, et al. CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis. Blood 2005;106:3524-31.
52. Yamamoto J, Barre-Sinoussi F, Bolton V, Pedersen N, Gardner M. Human alpha- and beta-interferon but not gamma- suppress the in vitro replication of LAV, HTLV-III, and ARV-2. J Interferon Res 1986; 6:143-52.
53. Allaway G, Davis-Bruno K, Beaudry G, et al. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV-1 isolates. AIDS Res Hum Retroviruses 1995;11:533-9.
54. Donzella G, Schols D, Lin S, et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 coreceptor. Nat Med 1998;4:72-7.
55. Shearer W, Israel R, Starr S, et al. Recombinant CD4-IgG2 in HIV-1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team. J Infect Dis 2000; 182:1774-9.
56. Jacobson J, Israel R, Lowy I, et al. Treatment of advanced HIV-1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother 2004;48:423-9.
57. Hendrix C, Flexner C, MacFarland R, et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000; 44:1667-73.
58. Martin L, Stricher F, Misse D, et al. Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nat Biotechnol 2003;21:71-6.
59. Vermeire K, Schols D. Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor. Expert Opin Investig Drugs 2005;14:1199-212.